Sign in

CIK 0001557746

  • Non-accelerated filer
  • Smaller reporting company

Aclaris Therapeutics, Inc.

Sign in to watch
Ticker
ACRS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
460571712
Phone
+1 484-324-7933
Business address
701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
  1. 4 Shares withheld for taxes Pres and CEO gave up 9,125 shares (to pay taxes)
  2. 4 Planned sale Chief Scientific Officer sold 6,000 shares at $5.08 ($30,460)
  3. 4 Open-market buy Chief Financial Officer bought 9,490 shares at $7.90 ($74,971)
  4. 4 Shares withheld for taxes Chief Financial Officer gave up 285 shares (to pay taxes)
  5. 4 Open-market buy Chief Business Officer bought 14,705 shares at $6.80 ($99,959)
  6. 4 Planned sale Chief Scientific Officer sold 6,000 shares at $7.32 ($43,895)
  7. 4 Shares withheld for taxes Pres and CEO gave up 4,437 shares (to pay taxes)
  8. 4 Shares withheld for taxes Chief Medical Officer gave up 5,407 shares (to pay taxes)
  9. 4 Exercise or conversion Director acquired 16,500 shares (option exercise)
  10. 4 Planned sale Chief Scientific Officer sold 6,000 shares at $10.28 ($61,663)
  11. 4 Exercise or conversion Director acquired 249 shares (option exercise)
  12. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  13. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  14. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  15. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  16. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  17. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  18. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  19. 4 Exercise or conversion Director acquired 4,507 shares (option exercise)
  20. 4 Open-market buy Pres and CEO bought 6,300 shares at $7.86 ($49,532)

Page 6 of 21 · 414 filings